A brain tumor trial will present new data at its first scientific meeting
Alpha Tau Medical Ltd. (DRTS) announced FDA approval to expand its REGAIN trial for recurrent glioblastoma to 20 patients, adding new endpoints. The company will present trial data at the 2026 Society for Neuro-Oncology Annual Meeting, marking the trial's first scientific presentation. The expanded study includes progression-free survival and quality-of-life assessments.
How this was made
The 30-second read
Why it matters
The IDE supplement approval signals regulatory confidence and may accelerate path to market if data are positive.
Market read
First‑time disclosure of trial expansion could move the stock and influence related biotech peers.
What to watch
Potential delays in IRB approvals at the three sites and competition from other glioblastoma therapies.
Background
Alpha Tau Medical Ltd. is an Israeli‑based developer of Alpha DaRT, an intratumoral alpha‑emitter therapy for solid tumors.
Ticker impact
FDA approves IDE supplement expanding Alpha Tau's REGAIN trial to 20 patients and adds new endpoints.
likely upward pressure as investors price in expanded clinical data opportunity
Regulatory approval of a larger trial is a material catalyst for a biotech with no product yet.
Market effects
May lift sentiment for the broader neuro‑oncology and alpha‑radiation therapy sector.
Positive for US biotech investors; limited global effect.
Modest, confined to niche cancer‑therapy space.
Counterpoint
If the trial fails to meet safety endpoints, the expansion could expose more risk and depress the stock.
Key entities
- CompanyAlpha Tau Medical Ltd.
Developer of Alpha DaRT therapy, listed on Nasdaq as DRTS.
- IndividualDr. Joshua Palmer
Principal investigator of the REGAIN study.
